Jeffrey Lawrence Schwartz Sells 3,890 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Jeffrey Schwartz sold 3,890 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.18, for a total value of $97,950.20. Following the completion of the sale, the director directly owned 7,019 shares of the company’s stock, valued at approximately $176,738.42. This trade represents a 35.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ:KMTS opened at $22.85 on Friday. The firm’s 50 day simple moving average is $25.34 and its 200 day simple moving average is $22.71. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -9.44 and a beta of 0.62. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. As a group, sell-side analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Trading of Kestra Medical Technologies

Hedge funds and other institutional investors have recently modified their holdings of the company. Corient Private Wealth LP lifted its holdings in shares of Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Kestra Medical Technologies by 2,366.0% during the second quarter. California State Teachers Retirement System now owns 686,422 shares of the company’s stock worth $17,463,000 after buying an additional 658,587 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares in the last quarter. Quantinno Capital Management LP acquired a new stake in Kestra Medical Technologies in the 1st quarter valued at approximately $431,000. Finally, Sei Investments Co. lifted its stake in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after acquiring an additional 43,753 shares in the last quarter.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
• Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
• Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
• Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KMTS. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price target for the company. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 31st. Finally, BTIG Research reiterated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.14.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.